[Evaluating the nutritional status of a lung cancer patient is an important element in patient management].
Nutritional status assessment during the comprehensive management of patients treated for cancer is becoming increasingly necessary. Various data are currently available which show a relationship between the nutritional status and certain morbidity-mortality parameters. In contrast, there is a paucity of data concerning lung cancer. A relationship between survival and the nutritional status has been found in the literature, exclusively in advanced stages of lung cancer. Unlike that observed in oncological digestive tract surgery, where artificial nutrition is recommended preoperatively in severely malnourished patients, no link has been evidenced between postoperative morbidity and mortality and the preoperative nutritional status in lung surgery. The scientific nutritional societies simply recommend preoperative nutritional assessment. Reflection on management of malnourished patients receiving chemotherapy is still "archaic" and recent studies and recommendations are lacking. Although largely prescribed, oral nutritional supplements have not proven efficient and patient compliance will probably have to be improved. According to "good nutrition practice" rules, the digestive tube should be used when it is functional and in theory, enteral nutrition is indicated in this situation. In addition to the lack of clinical studies, one of the obstacles to its use is cultural with the need to obtain not only patient approval but also that of the prescriber. Parenteral nutrition was discredited in earlier studies. It should probably be reevaluated in the context of new chemotherapeutic molecules and a different way of handling nutrition care. The physiological concept of omega-3 fatty acid modulation of inflammation is of interest in animal studies but the clinical modalities of use remain to be defined and determined. The role of nutrition in the management of lung cancer is still very limited but there are major expectations and many solutions are awaited in the coming years.
Antoun
S
S
Service des Urgences, Institut Gustave-Roussy, 39 Rue Camille-Desmoulins, 94805 Villejuif Cedex, France. antoun@igr.fr
Merad
M
M
Raynard
B
B
Ruffie
P
P
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002100:Cachexia / Q000401:mortality / Q000628:therapy; D004750:Enteral Nutrition; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy; D009752:Nutritional Status; D010166:Palliative Care / Q000379:methods*; D010348:Patient Care Team; D011502:Protein-Energy Malnutrition / Q000401:mortality / Q000628:therapy; D015996:Survival Rate
D000970:Antineoplastic Agents; D015525:Fatty Acids, Omega-3